Advice

following an abbreviated submission:

pegylated interferon alfa-2b (ViraferonPeg®) is accepted for use within NHS Scotland.

Indication under review: in a combination regimen with ribavirin for the treatment of children 3 years of age and older and adolescents, who have chronic hepatitis C, not previously treated, without liver decompensation, and who are positive for HCV-RNA.

This treatment involves a once weekly injection that reduces inconvenience to patients whilst increasing the response rate to pegylated interferon alfa-2b in combination with ribavirin.

Download detailed advice79KB (PDF)

Download

Medicine details

Medicine name:
pegylated interferon alfa-2b (Viraferon Peg)
SMC ID:
794/12
Indication:
in a combination regimen with ribavirin for the treatment of children 3 years of age and older and adolescents, who have chronic hepatitis C, not previously treated, without liver decompensation, and who are positive for HCV-RNA.
Pharmaceutical company
MSD
BNF chapter
Malignant disease and immunosuppression
Submission type
Abbreviated
Status
Superseded
Date advice published
09 July 2012
Additional notes

NICE MTA Advice: SMC Advice is superseded by National Institute for Health and Care Excellence (NICE) Multiple Technology Appraisal (MTA)